Eidos Therapeutics, A Bridgebio Company

This study aims to monitor the long-term safety of the drug acoramidis for people with a serious heart condition called transthyretin amyloid cardiomyopathy (ATTR-CM). It is open to 389 participants who successfully completed a prior 30-month clinical trial of the same drug. The …